XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
NATURE OF BUSINESS AND BASIS OF PRESENTATION - Liquidity (Details) - USD ($)
$ in Thousands
3 Months Ended
Aug. 02, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Aug. 31, 2023
Jul. 08, 2022
Acquisition of Combangio, Inc            
Common stock, shares issued   2,816,454   2,759,372    
Common stock, shares outstanding   2,816,454   2,759,372    
Common stock, authorized   120,000,000   120,000,000    
Net loss   $ (11,807) $ (14,455)      
Cash used in operations   (10,844) $ (9,684)      
Accumulated deficit   $ 641,216   $ 629,409    
Award agreement | California Institute for Regenerative Medicine (CIRM)            
Acquisition of Combangio, Inc            
Amount that may not be received if specific milestones are not met         $ 9,100  
Combangio, Inc. | Award agreement | California Institute for Regenerative Medicine (CIRM)            
Acquisition of Combangio, Inc            
Restricted grant $ 15,000          
Grant disbursement $ 5,900          
Commercial Business Sale to Alcon | Disposed of by sale not discontinued operations            
Acquisition of Combangio, Inc            
Amount receivable upon the achievement of specified commercial sales-based milestones           $ 325,000